Abbott Laboratories Corporation

Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Larry G Birkenmeyer

Suresh M Desai

Anthony Scott Muerhoff

George J Dawson

David J Hawksworth

Isa K Mushahwar

Robert N Ziemann

Bruce J Dille

Susan E Brophy

Bryan C Tieman

Bailin Tu

Thomas P Leary

Barry Lee Dowell

Cheng Zhao

Carol S Ramsay

Carolyn J Strobel

Philip M Hemken

Frank C Grenier

A Scott Muerhoff

John N Simons

James Carl Erker

Michelle Chalmers

Ruthie E Coffey

Joan D Tyner

John J Carrino

Tami J Pilot-Matias

Bernhard K Mueller

Dinesh O Shah

Jon D Kratochvil

Qiaoqiao Ruan

Sergey Y Tetin

Ronald L Marshall

Robert William Siegel

Robin A Gutierrez

Natalie A Solomon

Christopher C Marohnic

Ryan F Workman

John C Prostko

Andreas Popp

Gangamani S Beligere

Shanfun Ching

Elaine Marie Brate

Edward T Olejniczak

Thomas G Laffler

Hsiang-Yun Y Hu

Laurie A Rinehardt

Scott Muerhoff

M Felisha Bogdan

Shamila Manoj

Yoshihiro Ohhashi

Janet K Winkler

Yu Cheng

Barry L Dowell

Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.

Anti-GP73 monoclonal antibodies and methods of obtaining the same

The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.

HCV NS3 recombinant antigens and mutants thereof for improved antibody detection

Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders.

Composition and method for the diagnosis and treatment of iron-related disorders

The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.

Antibodies that bind to mammalian NGAL and uses thereof

The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of, and methods of using these polynucleotides and polypeptides in the detection ofantibodies or anti-antibodies in a subject. The invention finds particular useful application in identifying recent exposure to

[object Object]

The present invention relates to one or more peptides which may be used to test for the presence of antibodies to. These peptide are selected based on the strength and specificity of the human antibody response to. These peptides alone or in combination have a variety of uses, for example, as a component of a diagnostic assay or kit.

The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of thespeciesand. Such genes and proteins have many beneficial diagnostic as well as therapeutic uses.

The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of thespeciesandSuch genes and proteins have many beneficial diagnostic as well as therapeutic uses.

The subject invention relates to improvements in nucleic acid isolation, and more particularly, relates to modifications to the subtractive hybridization method and to reagents such as oligonucleotides that are useful when performing the method.

Method of performing subtractive hybridization using RDA

The present invention relates to nucleic oligomer primers or probes useful for detection of TTV in test samples. Also provided are assays which utilize these primers and probes, as well as test kits which contain these oligomer primers and/or probes. In addition, the present invention encompasses the use of TTV nucleotide sequences as nucleic acid vectors and as markers for determining transmission between individuals as well as the route thereof. Additionally, the present invention encompasses a method of detecting TTV infection prior to xenotransplatation of a tissue or organ.

Methods of utilizing the TT virus

The present invention provides a method for quantitatively detecting the amount of a target nucleic acid sequence which may be present in a test sample. A test sample which may contain a target nucleic acid sequence comprising target sequences X and Y is contacted with two primer sets, the first set being specific for target X and the second set being specific for target Y. The test sample also is contacted at the same time with an internal standard sequence IS, which is substantially derived from a combination of the first and second target sequences, and its corresponding oligonucleotide primers. Haptens are associated with the oligonucleotide primer sets in such a way that amplified target sequence products X and Y are detected by capture on a solid phase to which anti-hapten capture reagents are attached. A signal ratio of (X+Y)/S is determined to quantitate the amount of the target nucleic acid sequence contained in the sample.

Primer compositions and kits for detecting hepatitis B virus

HGBV-C oligonucleotides from the 5' end of HGBV-C useful for the detection and genotyping of HGBV-C isolates. Also provided are assays which utilize these oligonucleotides.

Detection of hepatitis GB virus genotypes

Growing community of inventors

Glenview, IL, United States of America

Larry G Birkenmeyer